Luo Jie, Bao Yu-Chen, Ji Xian-Xiu, Chen Bin, Deng Qin-Fang, Zhou Song-Wen
Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 507 Zhengmin Road, Shanghai 200433, China.
Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 507 Zhengmin Road, Shanghai 200433, China.
Biochem Biophys Res Commun. 2017 Feb 5;483(2):880-884. doi: 10.1016/j.bbrc.2017.01.027. Epub 2017 Jan 7.
SIRT2 is a NAD-dependent deacetylase and inhibition of SIRT2 has a broad anticancer activity. Here we report that SPOP binds to SIRT2 and mediates its degradation by the 26S proteasome, which can be blocked by MG132 treatment. We also found that the levels of SPOP significantly decreased, while the levels of SIRT2 significantly increased in non-small cell lung cancer (NSCLC) cell lines, compared to normal bronchial epithelial cell line and NSCLC specimens, compared to the paired non-tumor lung tissue. Furthermore, SPOP can suppress NSCLC cell growth. Notably, mutations in NSCLC inhibit the abilities of SPOP to degrade SIRT2 and suppress NSCLC cell growth. These results reveal a novel regulation of SIRT2 by SPOP mediated degradation, which is important for the growth of lung tumor cells.
SIRT2是一种依赖烟酰胺腺嘌呤二核苷酸(NAD)的脱乙酰酶,抑制SIRT2具有广泛的抗癌活性。在此我们报告,SPOP与SIRT2结合并介导其被26S蛋白酶体降解,MG132处理可阻断这种降解。我们还发现,与正常支气管上皮细胞系相比,非小细胞肺癌(NSCLC)细胞系中SPOP水平显著降低,而SIRT2水平显著升高;与配对的非肿瘤肺组织相比,NSCLC标本中也是如此。此外,SPOP可抑制NSCLC细胞生长。值得注意的是,NSCLC中的突变会抑制SPOP降解SIRT2以及抑制NSCLC细胞生长的能力。这些结果揭示了SPOP介导的降解对SIRT2的一种新调控,这对肺肿瘤细胞的生长很重要。